Chronic Stable Angina

ORBITA: What Goes Around, Comes Around… Or Does It?

Medical therapy has been the primary treatment for stable angina since nitroglycerin was first used in 1878. However, since the first successful percutaneous coronary intervention (PCI) procedure was performed in 1977, the role of PCI in patients with stable coronary artery disease (CAD) has been the subject of much study. Numerous trials have shown no reduction in death or myocardial infarction.1–5 However, these trials suggest that PCI is maybe more effective for managing angina symptoms than medical therapy alone.

Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris

Stable angina pectoris is the most prevalent clinical manifestation of coronary heart disease. While the overall prognosis in patients with stable angina is good, with a low yearly event rate of ~1–2 %,1 for many, adequate symptom control can be difficult to achieve, leading to significantly impaired quality of life.

Prediction of Post Percutaneous Coronary Intervention Myocardial Ischaemia

Myocardial revascularisation in patients with stable chronic angina is performed with the aim of reducing cardiovascular death, reducing myocardial infarction (MI) and relieving angina symptoms. However, contrary to expectations, modern therapy with percutaneous coronary intervention (PCI) has not had a significant impact on hard outcomes.1–5 Indeed, as also summarised in a recently published meta-analysis,6 PCI in stable angina patients does not reduce cardiovascular death or MI.

Fractional Flow Reserve Assessment of Coronary Artery Stenosis

Coronary artery disease (CAD) due to atherosclerosis is a major cause of morbidity and mortality. Early prevention of atherothrombotic disease with a healthy lifestyle (diet, exercise, optimal body weight and no smoking) is considered the best method of “treating” CAD, although increasing age remains associated with significant cardiovascular events.

The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelines

Chronic heart failure (HF), a complex and heterogeneous clinical syndrome, is a major cause of morbidity and mortality worldwide, and represents a major challenge to health care systems. The prevalence of HF and the number of hospitalisations is rising, even more in the ageing population.1 The direct costs of HF management reached 1–2 % of total health care expenditure and approximately two-thirds are attributable to hospitalisations.